ROIV
Roivant Sciences Ltd. (ROIV) Stock Analysis
Research Roivant Sciences Ltd. (ROIV) with company financials, earnings context, valuation indicators, risk analysis and related market news.
Research record updated: . Individual measures may refer to different reporting periods.
- Ticker
- ROIV
- Company
- Roivant Sciences Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $25.67B
- Financial data source
- FMP financial statements + FMP cash flow statements + FMP balance sheet + income statements + StockAnalysis complete statements
- Annual revenue (reporting year not supplied)
- $8.26M
- Annual net income (reporting year not supplied)
- $-299.77M
- Annual free cash flow (reporting year not supplied)
- $-758.56M
- Trailing revenue
- $7.53M
- Trailing net income
- $-266.25M
- Total assets
- $5.73B
- Total liabilities
- $435.63M
Roivant Sciences Ltd. (ROIV) Stock Analysis research
Roivant Sciences Ltd. develops medicines through specialized subsidiaries, focusing mainly on immune-mediated, inflammatory, dermatological, and rare diseases. Its portfolio includes Vtama (tapinarof), a nonsteroidal topical treatment for plaque psoriasis and atopic dermatitis, while batoclimab remains a major autoimmune pipeline catalyst. Recent Seeking Alpha and comparable investor coverage has emphasized clinical-readout potential, regulatory milestones, substantial liquidity, and the company’s ability to create value through focused subsidiaries, although sentiment remains sensitive to trial outcomes. The most important potential game changer is FcRn blockade, a technology designed to lower harmful antibody levels that drive autoimmune disease. Other differentiated programs target immune signaling through TYK2 or JAK pathways, potentially controlling inflammation more precisely than older broad immunosuppressants. Overall, Roivant offers meaningful scientific upside, but its investment case still depends more on future approvals and partnerships than on established commercial revenue. Within Healthcare, Roivant commands a sizable valuation and stronger recent momentum than many biotechnology peers, but it trades more on pipeline expectations and cash resources than on current sales, making it less conventionally valued than the broader market. My sector score is 7/10, and its sector-based value is 6/10: attractive for investors seeking biotechnology growth, but expensive and speculative compared with profitable healthcare companies. The market action is powerful and risk appetite is high, yet the large price swings mean setbacks could reverse gains quickly. In simple terms, Roivant has a strong financial cushion and little debt, but it is still losing money and using cash to fund research, so the future improves substantially only if clinical programs become approved products or valuable partnerships. Verdict: Bullish.
Review the available company profile, financial history, valuation context and investor signals for Roivant Sciences Ltd.. Compare the reported operating results with the valuation and risk measures below.
The figures are cached research data and can change after new filings, earnings reports or market updates. Verify material facts with primary company disclosures before making an investment decision.